JP2018509908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509908A5 JP2018509908A5 JP2017548953A JP2017548953A JP2018509908A5 JP 2018509908 A5 JP2018509908 A5 JP 2018509908A5 JP 2017548953 A JP2017548953 A JP 2017548953A JP 2017548953 A JP2017548953 A JP 2017548953A JP 2018509908 A5 JP2018509908 A5 JP 2018509908A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug
- host cell
- seq
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134981P | 2015-03-18 | 2015-03-18 | |
| US62/134,981 | 2015-03-18 | ||
| PCT/US2016/022943 WO2016149535A1 (en) | 2015-03-18 | 2016-03-17 | Cd48 antibodies and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020091335A Division JP2020141700A (ja) | 2015-03-18 | 2020-05-26 | Ｃｄ４８抗体及びその複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509908A JP2018509908A (ja) | 2018-04-12 |
| JP2018509908A5 true JP2018509908A5 (enExample) | 2019-03-07 |
| JP6892826B2 JP6892826B2 (ja) | 2021-06-23 |
Family
ID=56919489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548953A Expired - Fee Related JP6892826B2 (ja) | 2015-03-18 | 2016-03-17 | Ｃｄ４８抗体及びその複合体 |
| JP2020091335A Pending JP2020141700A (ja) | 2015-03-18 | 2020-05-26 | Ｃｄ４８抗体及びその複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020091335A Pending JP2020141700A (ja) | 2015-03-18 | 2020-05-26 | Ｃｄ４８抗体及びその複合体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10722592B2 (enExample) |
| EP (2) | EP3270965B1 (enExample) |
| JP (2) | JP6892826B2 (enExample) |
| KR (1) | KR20170128256A (enExample) |
| CN (1) | CN107530422B (enExample) |
| AU (1) | AU2016232839B2 (enExample) |
| BR (1) | BR112017019617A2 (enExample) |
| CA (1) | CA2976740A1 (enExample) |
| DK (1) | DK3270965T3 (enExample) |
| EA (2) | EA035374B1 (enExample) |
| ES (1) | ES2795818T3 (enExample) |
| IL (1) | IL254027B (enExample) |
| MX (1) | MX382582B (enExample) |
| SG (1) | SG11201706786UA (enExample) |
| WO (1) | WO2016149535A1 (enExample) |
| ZA (1) | ZA201705935B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102626498B1 (ko) | 2016-03-25 | 2024-01-19 | 씨젠 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
| US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| WO2019229536A2 (en) | 2018-05-29 | 2019-12-05 | Intocell, Inc. | Novel benzodiazepine derivatives and uses thereof |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CA3118026A1 (en) | 2018-10-31 | 2020-05-07 | Intocell, Inc. | Fused heterocyclic benzodiazepine derivatives and uses thereof |
| WO2020163225A1 (en) | 2019-02-05 | 2020-08-13 | Seattle Genetics, Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
| CN114269749B (zh) | 2019-06-10 | 2024-10-01 | 苏特罗生物制药公司 | 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物 |
| KR20220075351A (ko) | 2019-10-04 | 2022-06-08 | 씨젠 인크. | 항-pd-l1 항체 및 항체-약물 접합체 |
| KR20220079606A (ko) | 2019-10-04 | 2022-06-13 | 씨젠 인크. | 캄프토테신 펩티드 접합체 |
| WO2021067820A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
| BR112022020332A2 (pt) | 2020-04-10 | 2022-12-13 | Seagen Inc | Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune |
| WO2022115451A1 (en) * | 2020-11-24 | 2022-06-02 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| CR20230283A (es) | 2020-11-24 | 2023-07-27 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos |
| CA3213636A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| IL308795A (en) | 2021-05-28 | 2024-01-01 | Seagen Inc | Anthracycline antibody conjugates |
| IL315508A (en) | 2022-03-17 | 2024-11-01 | Seagen Inc | Camptothecin conjugates |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| DK4601703T3 (da) | 2023-04-18 | 2026-05-11 | Astrazeneca Ab | Konjugater omfattende spaltelige linkere |
| TW202525851A (zh) | 2023-08-15 | 2025-07-01 | 瑞典商阿斯特捷利康公司 | 包含可切割連接子的軛合物 |
| WO2025090774A1 (en) | 2023-10-24 | 2025-05-01 | Seagen Inc. | Chemotherapeutic compounds and methods of use |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2025185617A1 (en) * | 2024-03-05 | 2025-09-12 | Hutchmed Limited | Linker, antibody-drug conjugate and use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| CA2249998A1 (en) * | 1996-03-27 | 1997-10-02 | Crc For Biopharmaceutical Research Pty. Ltd. | The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| EP1749538A4 (en) * | 2004-03-31 | 2009-11-11 | Kirin Pharma Kk | METHOD FOR DETERMINING THE DIFFERENTIATION OF REGULATORY T CELLS AND THEIR PROLIFERATION WITH GPI ANCHOR PROTEIN AGONISTS AND MEDICINAL COMPOSITION THEREFOR |
| SG173322A1 (en) * | 2004-04-16 | 2011-08-29 | Macrogenics Inc Dw Us | Fc gammad riib - specific antibodies and methods of use thereof |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| SI1912671T1 (en) * | 2005-07-18 | 2018-01-31 | Seattle Genetics, Inc. | Conjugates beta-glucuronide linker-drug |
| HUE039865T2 (hu) * | 2005-12-20 | 2019-02-28 | Sbi Biotech Co Ltd | Anti-ILT7 antitest |
| WO2009052431A2 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| MX2010005282A (es) * | 2007-11-13 | 2010-08-31 | Teva Pharma | Anticuerpos humanizados contra tl1a. |
| WO2009099580A2 (en) * | 2008-02-05 | 2009-08-13 | Monsanto Technology, Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
| US9097717B2 (en) * | 2009-04-10 | 2015-08-04 | Osaka University | Methods of killing myeloma stem and precursor cells by administering anti-CD48 antibodies |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| AR083044A1 (es) * | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| US9409987B2 (en) * | 2011-04-15 | 2016-08-09 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| AU2013229786B2 (en) | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| AU2013263002C1 (en) * | 2012-05-15 | 2018-05-31 | Seagen Inc. | Self-stabilizing linker conjugates |
| AU2014337555C1 (en) * | 2013-10-15 | 2021-01-28 | Seagen Inc. | PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics |
-
2016
- 2016-03-17 EA EA201792055A patent/EA035374B1/ru unknown
- 2016-03-17 US US15/557,910 patent/US10722592B2/en active Active
- 2016-03-17 SG SG11201706786UA patent/SG11201706786UA/en unknown
- 2016-03-17 EA EA201992756A patent/EA201992756A3/ru unknown
- 2016-03-17 CA CA2976740A patent/CA2976740A1/en not_active Abandoned
- 2016-03-17 JP JP2017548953A patent/JP6892826B2/ja not_active Expired - Fee Related
- 2016-03-17 BR BR112017019617-4A patent/BR112017019617A2/pt not_active IP Right Cessation
- 2016-03-17 ES ES16765773T patent/ES2795818T3/es active Active
- 2016-03-17 DK DK16765773.3T patent/DK3270965T3/da active
- 2016-03-17 MX MX2017011432A patent/MX382582B/es unknown
- 2016-03-17 KR KR1020177024226A patent/KR20170128256A/ko not_active Withdrawn
- 2016-03-17 CN CN201680013161.1A patent/CN107530422B/zh not_active Expired - Fee Related
- 2016-03-17 EP EP16765773.3A patent/EP3270965B1/en not_active Not-in-force
- 2016-03-17 EP EP19219476.9A patent/EP3662933A1/en not_active Withdrawn
- 2016-03-17 AU AU2016232839A patent/AU2016232839B2/en not_active Ceased
- 2016-03-17 WO PCT/US2016/022943 patent/WO2016149535A1/en not_active Ceased
-
2017
- 2017-08-16 IL IL254027A patent/IL254027B/en active IP Right Grant
- 2017-08-31 ZA ZA2017/05935A patent/ZA201705935B/en unknown
-
2020
- 2020-05-26 JP JP2020091335A patent/JP2020141700A/ja active Pending
- 2020-06-04 US US16/892,529 patent/US20200289661A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3093327C (en) | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof | |
| ES2701188T3 (es) | Conjugados anticuerpo-fármaco e inmunotoxinas | |
| US10752690B2 (en) | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses | |
| AU2014224928B2 (en) | Amatoxin derivatives | |
| JP5993940B2 (ja) | 生体直交型薬物活性化 | |
| JP2024522389A (ja) | 抗体薬物複合体の調製方法および使用 | |
| ES2939494T3 (es) | Conjugados de fármaco anticuerpo que comprenden derivados de ecteinascidina | |
| US20200392108A1 (en) | Antibody-drug conjugates and related compounds, compositions and methods | |
| CN117295526B (zh) | 制备工程化抗体的高度均质性抗体-药物偶联物的方法 | |
| JP6321687B2 (ja) | アマトキシン誘導体 | |
| JP2016523810A5 (enExample) | ||
| JP2018524373A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| JP2014515040A5 (enExample) | ||
| JP2016503295A5 (enExample) | ||
| JP2025517476A5 (enExample) | ||
| JP2022500486A (ja) | 抗体−ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| FI3525828T3 (fi) | Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja | |
| JP2019534706A5 (enExample) | ||
| JP7854462B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| WO2023163227A1 (ja) | 抗体－薬物コンジュゲート | |
| EA201892343A1 (ru) | Новые в7-н3 связывающие молекулы, содержащие их конъюгаты антитело-лекарственное средство и способы их применения | |
| NZ773646A (en) | Amatoxin-antibody conjugates | |
| NZ730450B2 (en) | Binding molecules, especially antibodies, binding to l1cam (cd171) | |
| NZ773646B2 (en) | Amatoxin-antibody conjugates |